Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS(R) T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. The company's lead product candidate includes EB103 and EB104. Estrella Immunopharma Inc., formerly known as TradeUP Acquisition Corp., is based in NEW YORK.
Info & Links
CEO
Cheng Liu
Headquarters
5858 Horton Street, Suite 370 Emeryville, CA 94608, UNITED STATES
Estrella Immunopharma, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
33.83M
Enterprise Value
32.03M
Enterprise Value/EBITDA(ttm)
-3.63
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
72.29
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
-195.77%
Return on Invested Capital(ttm)
-561.73%
Return on Assets(ttm)
-157.28%
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-8.82M
Net Income Available to Common(ttm)
-8.82M
Diluted EPS(ttm)
-0.26
Share Statistics
Beta (5Y Monthly)
0.41
52-Week Change
-6.86%
S&P 500 52-Week Change
7.67%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
36.18M
Dividend Yield
0.00%
Float4
16.24M
% Held by Insiders
55.10%
% Held by Institutions
0.35%
Balance Sheet
Total Cash(mrq)
1.80M
Total Cash Per Share(mrq)
0.05
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
0.75%
Quick Ratio(mrq)
0.75%
Book Value Per Share(mrq)
0.02
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.06
Free Cash Flow(ytd)
-2.22M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.